Inhibrx Biosciences (INBX) Stock Price, Quote, News & History | Benzinga

Inhibrx Biosciences Inc (INBX) Stock Price, Quote, News & History

INBXNASDAQ

Trade with Public

Trade with Public

$124.66

-2.04-1.61%

At close: Aug 31, 5:00 PM EST

$124.00

-2.70-2.13%

Pre-Market: 7:33 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$124.66

Volume / Avg.

2.32K / 301.40K

Day Range

- - -

52 Wk Range

26.19 - 155.29

Market Cap

$1.82B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

71

Short Interest

29.17%

Days to Cover

14.39

Recent Inhibrx Biosciences Inc News

Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study

Inhibrx Biosciences shares rise after Phase 2 INBRX-106 and Keytruda data showed stronger response rates in head and neck cancer.

Vandana Singh

Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

Inhibrx explores spin-off of INBRX-106 amid Big Pharma interest, with potential valuation exceeding $9 billion pending trial outcomes.

Vandana Singh

GE Vernova, Boston Scientific, Intuitive Surgical And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were higher, with the Dow Jones gaining over 350 points on Wednesday. GE Vernova shares rose 14.1% after beating estimates and raising sales guidance.

Avi Kapoor

Dow Jumps Over 400 Points; Boeing Posts Upbeat Q1 Results

US stocks rise, with Dow gaining over 400 points. Dow up 0.87%, NASDAQ up 0.70%, S&P 500 up 0.69%. Utilities sector jumps 1.4%, financials only up 0.1%.

Avi Kapoor

This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

Top Wall Street analysts changed outlook on top names. See complete rating changes, including upgrades and downgrades, on Benzinga's analyst ratings page.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-131.89M

Investing Cash Flow (TTM)

-7.00K

Financing Cash Flow (TTM)

78.67M

Free Cash Flow (TTM)

-131.90M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-53.22M

Analyst Trends and Forecast

1

Apr

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.88B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-7.15%

Earnings Yield % (FWD)

-6.82%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$3.60

Company Debt

Total Debt

$176.29M

LT Debt

$176.29M

LT Debt Issuance (TTM)

$74.99M

LT Debt Repayment (TTM)

-

Total Cash

$133.34M

Debt to Equity

-

Issuance of Debt (TTM)

$74.99M

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$124.66

Volume / Avg.

2.32K / 301.40K

Day Range

- - -

52 Wk Range

26.19 - 155.29

Market Cap

$1.82B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

71

Short Interest

29.17%

Days to Cover

14.39

About

Sector

Health Care

Industry

Biotechnology

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates inc...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Inhibrx Biosciences (INBX) stock?

A

You can purchase shares of Inhibrx Biosciences (NASDAQ:INBX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Inhibrx Biosciences (INBX) competitors?

A

Other companies in Inhibrx Biosciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Inhibrx Biosciences (INBX) stock?

A

Inhibrx Biosciences has a consensus price target of $197.50.

Q

What is the current price for Inhibrx Biosciences (INBX)?

A

The stock price for Inhibrx Biosciences (NASDAQ: INBX) is $124 last updated September 2, 2026 at 7:01 AM EDT.

Q

Does Inhibrx Biosciences (INBX) pay a dividend?

A

There are no upcoming dividends for Inhibrx Biosciences.

Q

When is Inhibrx Biosciences (NASDAQ:INBX) reporting earnings?

A

Inhibrx Biosciences does not have any upcoming earnings scheduled.

Q

Is Inhibrx Biosciences (INBX) going to split?

A

There is no upcoming split for Inhibrx Biosciences.

Q

What sector and industry does Inhibrx Biosciences (INBX) operate in?

A

Inhibrx Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.